ArticleJournal of the American Heart Association2025
Endothelial Cell-Related Proteins in Plasma Predict Major Adverse Cardiovascular Events and Worsening Heart Failure in Patients With Hypertrophic Cardiomyopathy.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Machine learning and multi-omics technologies for precision cardiovascular medicine: advancing diagnosis, risk prediction, and therapeutic guidance.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundHypertrophic cardiomyopathy (HCM) often causes major adverse cardiovascular events (MACE) and worsening heart failure (HF). Endothelial cell (EC) dysfunction is known to be involved in the pathogenesis of HCM. However, the prognostic value of proteins related to EC function (EC-related proteins) in HCM is unknown.
methodsIn this prospective cohort study of patients with HCM, we measured plasma levels of 90 EC-related proteins upon enrollment. The primary outcome measure was MACE. The secondary outcome measure was worsening HF. We developed machine learning models based on EC-related proteins to predict MACE or worsening HF using data from one institution (training set). We tested the predictive ability in independent samples from the other institution (test set) and performed time-to-event analyses.
resultsThe study included 722 patients (n=458 in the training set and n=264 in the test set). Using our EC-related protein-based model, the area under the receiver-operating-characteristic curve to predict MACE was 0.71 (95% CI, 0.64-0.77) and that for worsening HF was 0.71 (95% CI, 0.63-0.79). When we divided the test set into low- and high-risk groups according to the predicted probabilities derived from the training set, the high-risk groups had significantly higher risks of developing MACE and worsening HF compared with the low-risk groups (both
conclusionsThe present prospective study demonstrated that EC-related proteins in plasma predict MACE and worsening HF in patients with HCM. These EC-related proteins have a potential to become novel biomarkers for risk stratification in HCM to improve current prediction models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.